Previous 10 | Next 10 |
Syneos Health Inc. (NASDAQ:SYNH) said it's not engaged in discussions on a potential combination or transaction with LabCorp. (NYSE:LH) or any of its businesses or divisions, according to an 8-K filing. Syneos rose 4.5% in premarket trading, LabCorp. fell 1.1%. The disclosure comes ...
MORRISVILLE, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that the Company is scheduled to present at two upcoming investor conferences: Chief Executive Officer Ali...
Syneos Health Inc. (NASDAQ:SYNH) traded today at a new 52-week high of $103.82. So far today approximately 121,000 shares have been exchanged, as compared to an average 30-day volume of 501,000 shares. Syneos Health Inc. (NASDAQ:SYNH) defies analysts with a current price ($103.56) 26.1% ...
CFRA has upgraded shares of Syneos Health (SYNH +2.9%) to buy from hold citing a "strong demand environment for CROs with its robust pipeline." The firm has a $108 price target (8% upside). Analyst Sel Hardy writes that Syneos' recent acquisitions of StudyKIK and RxDataScience allow the compa...
Shares of Syneos Health Inc. (NASDAQ:SYNH) traded today at $101.23, eclipsing its 52-week high. This new high was reached on below average trading volume as 121,000 shares traded hands, while the average 30-day volume is approximately 521,000 shares. In the past 52 weeks, Syneos Health I...
Syneos Health, Inc. (SYNH) Q3 2021 Earnings Conference Call November 3, 2021 08:00 ET Company Participants Ronnie Speight - Senior Vice President of Investor Relations Alistair Macdonald - Chief Executive Officer Jason Meggs - Chief Financial Officer Paul Colvin - President of Clinical Soluti...
Image source: The Motley Fool. Syneos Health, inc (NASDAQ: SYNH) Q3 2021 Earnings Call Nov 3, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Syneos Health, inc (SYNH) Q3 2021 Earnings Call Transcript
Highlights Third quarter revenue of $1,348.2 million increased 22.7% year-over-year. Clinical Solutions net new business awards of $1,353.8 million for the third quarter, representing year-over-year growth of 35.0% and a book-to-bill ratio of 1.30x, and $5,322.2 million for th...
Syneos Health (NASDAQ:SYNH) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open. The consensus EPS Estimate is $1.17 (+12.5% Y/Y) and the consensus Revenue Estimate is $1.34B (+21.8% Y/Y). Over the last 2 years, SYNH has beaten EPS estimates 100% of the...
AAWW, ACLS, ACRE, AGIO, AMRN, AMRX, ATH, ATY, AUPH, AUTL, AVA, BCRX, BDC, BDSI, BGCP, BIP, OTCPK:BMWYY, BR, BRSP, BWA, CDW, CIM, CIO, CLH, CLVS, CPRI, CRL, CRTO, CSTE, CTRA, CVE, CVS, CWH, DFIN, DISCA, OTCQX:DLAKF, OTCPK:DNNGY, DNOW, EAT, EMR, ES, ETR, EVRG, EVRI, EXC, EXPI, EYPT, FDP, FUN, F...
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...